Gastrin-Releasing Peptide Receptor Targeting PET/CT With 68Ga-NOTA-RM26 in the Assessment of Glioma and Combined Multiregional Biopsies.

Purpose: The aim of this study was to investigate the value of 68Ga-NOTA-RM26 (68Ga-RM26), a gastrin-releasing peptide receptor-targeting antagonist labeled with the radionuclide 68Ga, in the diagnosis of high-grade gliomas and in combination with multiregional biopsies using PET/CT.

Patients And Methods: After institutional review board approval and informed consent, a total of 35 patients with suspected glioma lesions were enrolled in this study. All patients underwent 68Ga-RM26 PET/CT scans within 2 weeks before surgery.

Head-to-Head Comparison of [Ga]Ga-NOTA-RM26 and [F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study.

Gastrointestinal stromal tumors (GISTs) are the most common stromal tumors in the gastrointestinal tract. This study was designed to evaluate a gastrin-releasing peptide receptor antagonist PET tracer, [Ga]Ga-NOTA-RM26, and compare it with [F]FDG PET/CT in the assessment of patients with GISTs. With institutional review board approval and informed consent, 30 patients with suspected or proven GISTs based on abdominal CT or gastroscopy were recruited.

Evaluation of Angiotensin-Converting Enzyme 2 Expression with Novel Ga-Labeled Peptides Originated from the Coronavirus Receptor-Binding Domain.

Angiotensin-converting enzyme 2 (ACE2) is not only a key to the renin-angiotensin-aldosterone system and related diseases, but also the main entry point on cell surfaces for certain coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2. By analyzing the different key binding sites from the receptor-binding domain (RBD) of SARS-CoV and SARS-CoV-2, nine new ACE2-targeting peptides (A to A) were designed, synthesized and connected with a chelator, 1,4,7-triazacyclononane-'-triacetic acid (NOTA). NOTA-A, NOTA-A, NOTA-A, NOTA-A, and NOTA-A were successfully labeled with [Ga]Ga and were used for biological evaluation.

Dual targeting PET tracer [Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study.

Early discovery, accurate diagnosis, and staging of lung cancer is essential for patients to receive appropriate treatment. PET/CT has become increasingly recognized as a valuable imaging modality for these patients, but there remains room for improvement in PET tracers. We aimed to evaluate the feasibility of using [Ga]Ga-FAPI-RGD, a dual-targeting heterodimeric PET tracer that recognizes both fibroblast activation protein (FAP) and integrin αβ for detecting lung neoplasms, by comparing it with [F]FDG and single-targeting tracers [Ga]Ga-RGD and [Ga]Ga-FAPI.